Stoke Therapeutics
Price & Volume
Stats
See moreOpen | $30.43 |
Previous Close | $29.90 |
Day Range | $28.40-$31.08 |
52W Range | $5.35-$32.40 |
Market Cap | $1.6B |
Shares Short | 11M |
Financials
See moreRevenue (12 Mos) | $199.8M |
Revenue Growth (YoY) | 186% |
Gross Profit (12 Mos) | $199.8M |
Diluted EPS | $0.87 |
News
See moreYahoo Finance • 2 days ago
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Yahoo Finance • 5 days ago
Stoke Therapeutics Names Ian Smith As CEO; Phase 3 Trial Of Zorevunersen Underway
Yahoo Finance • 26 days ago
7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?
About
CEO | Mr. Ian F. Smith A.C.A., C.P.A. |
Address | 45 Wiggins Avenue, Bedford, MA, United States, 01730 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 128 |
